Amgen's Kyprolis wins FDA myeloma nod; AZ sells thyroid drug to Sanofi's Genzyme;

> The FDA has approved Kyprolis for combo use in the treatment of patients with relapsed multiple myeloma. Release

> Bristol-Myers Squibb's ($BMY) hep C pill, Daklinza, has won FDA approval to be used in combination with Gilead's ($GILD) Sovaldi. Release

> AstraZeneca ($AZN) has inked a $300 million pact to sell thyroid carcinoma drug Caprelsa to Sanofi's ($SNY) Genzyme. Story

> After the close of Teva's ($TEVA) $40.5 billion deal for Allergan's generics business, the Israeli drugmaker will boast a commercial presence in 100 markets, including a top-three position in more than 40 of those markets, it said Monday. Release

And Finally... Television's Dr. Oz made $1.17 million off a hemorrhoid treatment he promoted in his column, Vox reports. More

Suggested Articles

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.